An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease (HORIZON PLUS)
This study has been terminated.
First Posted: March 11, 2010
Last Update Posted: October 12, 2016
Information provided by (Responsible Party):
An open-label extension study of the HORIZON protocol evaluating the safety of dimebon (latrepirdine)in subjects with Huntington disease.
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Medivation, Inc.:
|Study Start Date:||February 2010|
|Primary Completion Date:||June 2011 (Final data collection date for primary outcome measure)|
Experimental: Dimebon (latrepirdine)
Patients receive dimebon 10mg orally 3 times per day for 1 week and 20 mg orally 3 times per day thereafter.
|Drug: Dimebon (latrepirdine)|
Contacts and Locations
No Contacts or Locations Provided